CTIS2024-512504-19-00招募中1 期
1456-0001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapyMetastatic pancreatic ductal adenocarcinoma (mPDAC)MedDRA version: 21.0Level: LLTClassification code: 10033599Term: Pancreatic adenocarcinoma metastatic Class: 10029104CTIS2023-508998-85-00Boehringer Ingelheim International GmbH68
进行中（未招募）
1 期
A study in healthy men to test whether BI 1015550 influences the amount of nintedanib and pirfenidone in the bloodHealthy volunteer trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2023-505522-34-00Boehringer Ingelheim International GmbH14
进行中（未招募）
1 期
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104Prostate cancerCTIS2023-506435-15-00Bayer Consumer Care AG60
招募中
1 期
A study in women with overweight or obesity to test whether different doses of BI 456906 influence the amount of a contraceptive in the bloodpharmacokinetic trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2022-503146-53-00Boehringer Ingelheim International GmbH24
进行中（未招募）
1 期
A study in healthy men to test how BI 1291583 is taken up by the bodyHealthy volunteer trialMedDRA version: 21.0Level: LLTClassification code: 10053349Term: Pharmacokinetic study Class: 10022891CTIS2023-505683-11-00Boehringer Ingelheim International GmbH25